Immuneering’s (IMRX) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research note published on Thursday morning,Benzinga reports. The brokerage currently has a $12.00 price target on the stock.

Several other analysts also recently commented on IMRX. Chardan Capital reaffirmed a “buy” rating and set a $13.00 price objective on shares of Immuneering in a research report on Monday, March 24th. Morgan Stanley cut shares of Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th.

Immuneering Stock Up 4.0 %

IMRX stock opened at $1.29 on Thursday. The firm has a market cap of $46.29 million, a price-to-earnings ratio of -0.65 and a beta of -0.25. The company’s fifty day simple moving average is $1.61 and its 200 day simple moving average is $1.92. Immuneering has a 12-month low of $1.00 and a 12-month high of $3.83.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.16). Research analysts expect that Immuneering will post -1.86 earnings per share for the current year.

Institutional Investors Weigh In On Immuneering

Hedge funds and other institutional investors have recently modified their holdings of the company. HighTower Advisors LLC grew its position in Immuneering by 21.4% in the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after purchasing an additional 9,400 shares during the period. Rockefeller Capital Management L.P. acquired a new position in shares of Immuneering during the fourth quarter valued at about $390,000. XTX Topco Ltd increased its position in shares of Immuneering by 177.2% during the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock worth $72,000 after acquiring an additional 20,871 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Immuneering in the 4th quarter worth about $47,000. Finally, Bridgeway Capital Management LLC lifted its position in Immuneering by 77.4% in the 4th quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company’s stock valued at $113,000 after acquiring an additional 22,400 shares in the last quarter. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.